Search

Background: Using data collected in the prospective observational study CIRSE Registry for SIR-Spheres Therapy, the present study aimed at identifying predictors of adverse events (AEs) following transarterial radioembolization (TARE) with Yttrium-90 resin microspheres for liver tumours. Methods: We analysed 1027 patients enrolled between January 2015 and December 2017 and followed up for 24 months. Four hundred and twenty-two patients with hepatocellular carcinoma (HCC), 120 with intrahepatic carcinoma (ICC), 237 with colorectal liver metastases and 248 with liver metastases from other primaries were included. Prognostic factors were calculated with a univariable analysis by using the overall AEs burden score (AEBS). Results: All-cause AEs were reported in 401/1027 (39.1%) patients, with AEs associated with TARE, such as abdominal pain (16.6%), fatigue (17%), and nausea (11.7%) reported most frequently. Grade 3 or higher AEs were reported in 92/1027 (9%) patients. Reports on grade ≥ 3 gastrointestinal ulcerations (0.4%), gastritis (0.3%), radiation cholecystitis (0.2%) or radioembolization-induced liver disease (0.5%) were uncommon. Univariable analysis showed that in HCC, AEBS increased for Eastern Cooperative Oncology Group (ECOG) 0 (p = 0.0045), 1 tumour nodule (0.0081), > 1 TARE treatment (p = 0.0224), no prophylactic embolization (p = 0.0211), partition model dosimetry (p = 0.0007) and unilobar treatment target (0.0032). For ICC, > 1 TARE treatment was associated with an increase in AEBS (p = 0.0224), and for colorectal liver metastases, ECOG 0 (p = 0.0188), > 2 prior systemic treatments (p = 0.0127), and 1 tumour nodule (p = 0.0155) were associated with an increased AEBS. Conclusion: Our study confirms that TARE is a safe treatment with low toxicity and a minimal impact on quality of life. [ABSTRACT FROM AUTHOR]

Abstract: Global Monitoring for Environment and Security (GMES) is a joint initiative of the European Commission (EC) and the European Space Agency (ESA), designed to establish a European capacity for the provision and use of operational monitoring information for environment and security applications. ESA''s role in GMES is to provide the definition and the development of the space- and ground-related system elements. GMES Sentinel-2 mission provides continuity to services relying on multi-spectral high-resolution optical observations over global terrestrial surfaces. The key mission objectives for Sentinel-2 are: (1) To provide systematic global acquisitions of high-resolution multi-spectral imagery with a high revisit frequency, (2) to provide enhanced continuity of multi-spectral imagery provided by the SPOT (Satellite Pour l''Observation de la Terre) series of satellites, and (3) to provide observations for the next generation of operational products such as land-cover maps, land change detection maps, and geophysical variables. Consequently, Sentinel-2 will directly contribute to the Land Monitoring, Emergency Response, and Security services. The corresponding user requirements have driven the design toward a dependable multi-spectral Earth-observation system featuring the Multi Spectral Instrument (MSI) with 13 spectral bands spanning from the visible and the near infrared to the short wave infrared. The spatial resolution varies from 10m to 60m depending on the spectral band with a 290km field of view. This unique combination of high spatial resolution, wide field of view and spectral coverage will represent a major step forward compared to current multi-spectral missions. The mission foresees a series of satellites, each having a 7.25-year lifetime over a 15-year period starting with the launch of Sentinel-2A foreseen in 2013. During full operations two identical satellites will be maintained in the same orbit with a phase delay of 180° providing a revisit time of five days at the equator. This paper provides an overview of the GMES Sentinel-2 mission including a technical system concept overview, image quality, Level 1 data processing and operational applications. [Copyright &y& Elsevier]